Kyverna’s miv-cel shows sustained benefit in Phase 1 progressive multiple sclerosis trial
KYTX•Updated Phase 1 results for Kyverna Therapeutics’ miv-cel showed stable or improved disability in all five evaluable patients in a six-patient progressive multiple sclerosis study; four sustained benefit through one year. The treatment was well tolerated, and Kyverna expects to update its development strategy by early 2027.
1. Trial results
Kyverna Therapeutics announced updated Phase 1 results for miv-cel in progressive multiple sclerosis. All five evaluable patients in the six-patient study had stable or improved disability, with four sustaining benefit through one year. Four patients maintained improvement beyond one year without chronic immunotherapies, and the first treated patient sustained clinical benefit beyond two years.
2. Safety and next steps
Treatment was well tolerated, with no high-grade CRS or reported cases of ICANS or IEC-HS. Miv-cel received RMAT designation for non-active secondary progressive multiple sclerosis, and Kyverna expects to provide a development strategy update by early 2027.
